Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1991 1
1993 2
1994 1
1995 2
1996 1
1998 3
1999 1
2000 3
2001 1
2002 2
2003 2
2006 2
2007 1
2008 2
2009 2
2011 2
2012 4
2013 4
2014 2
2015 2
2017 1
2020 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in patients with mild to moderate hypertension.
Lewin AJ, Lueg MC, Targum S, Cardenas P. Lewin AJ, et al. Clin Cardiol. 1993 Oct;16(10):732-6. doi: 10.1002/clc.4960161009. Clin Cardiol. 1993. PMID: 8222387 Free article. Clinical Trial.
This is the first study to demonstrate the 24-h effectiveness of the bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination, using 24-h ambulatory BP monitoring. In addition, antihypertensive therapy with low doses of bisoprolol/hydrochlorothiazide in …
This is the first study to demonstrate the 24-h effectiveness of the bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination, …
[The clinical efficiency and safety of bisoprolol hydrochlorothiazide in patients with mild to moderate essential hypertension].
Jiang H, Ke YN; Lodoz Working Group. Jiang H, et al. Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Jul;34(7):605-8. Zhonghua Xin Xue Guan Bing Za Zhi. 2006. PMID: 17081362 Clinical Trial. Chinese.
OBJECTIVE: To investigate the efficacy and safety of bisoprolol/hydrochlorothiazide (Lodoz) in patients with mild and moderate essential hypertension. ...
OBJECTIVE: To investigate the efficacy and safety of bisoprolol/hydrochlorothiazide (Lodoz) in patients with mild and moderate …
Clinical results with bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg combination in systolic hypertension in the elderly.
Benetos A, Adamopoulos C, Argyriadis P, Bean K, Consoli S, Safar M. Benetos A, et al. J Hypertens Suppl. 2002 Feb;20(1):S21-5. J Hypertens Suppl. 2002. PMID: 11996196 Review.
A randomized, multicentre, double-blind, parallel group study was conducted to compare the efficacy and safety of bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg (biso 2.5/HCTZ 6.25) (n = 84) versus amlodipine 5 mg (n = 80) in subjects over 60years of age with isolate …
A randomized, multicentre, double-blind, parallel group study was conducted to compare the efficacy and safety of bisoprolol 2.5 mg/ …
A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide.
Frishman WH, Bryzinski BS, Coulson LR, DeQuattro VL, Vlachakis ND, Mroczek WJ, Dukart G, Goldberg JD, Alemayehu D, Koury K. Frishman WH, et al. Arch Intern Med. 1994 Jul 11;154(13):1461-8. Arch Intern Med. 1994. PMID: 8018001 Clinical Trial.
METHODS: A total of 512 patients with mild to moderate essential hypertension were randomized to once-daily treatment with bisoprolol (0, 2.5, 10, or 40 mg), hydrochlorothiazide (0, 6.25, or 25 mg), and all possible combinations. ...The addition of hydrochlorothi
METHODS: A total of 512 patients with mild to moderate essential hypertension were randomized to once-daily treatment with bisoprolol
Short-term electrophysiological effects of losartan, bisoprolol, amlodipine, and hydrochlorothiazide in hypertensive men.
Porthan K, Viitasalo M, Hiltunen TP, Vaananen H, Dabek J, Suonsyrja T, Hannila-Handelberg T, Virolainen J, Nieminen MS, Toivonen L, Kontula K, Oikarinen L. Porthan K, et al. Ann Med. 2009;41(1):29-37. doi: 10.1080/07853890802195211. Ann Med. 2009. PMID: 18608135 Free article. Clinical Trial.
METHODS: A total of 183 hypertensive men received for 4 weeks drugs (losartan 50 mg, bisoprolol 5 mg, amlodipine 5 mg, hydrochlorothiazide (HCTZ) 25 mg) in a randomized order, separated by 4-week placebo periods. ...Amlodipine had no repolarization effects, whereas …
METHODS: A total of 183 hypertensive men received for 4 weeks drugs (losartan 50 mg, bisoprolol 5 mg, amlodipine 5 mg, hydrochloro
[Efficacy and tolerance of the bisoprolol/hydrochlorothiazide combination in arterial hypertension].
Luna RL, Oigman W, Ramirez JA, Mion D, Batlouni M, da Rocha JC, Feitosa GS, Castro I, Chaves Júnior Hde C, God EM, Maia LN, Ortega KC, Raineri AM. Luna RL, et al. Arq Bras Cardiol. 1998 Oct;71(4):601-8. doi: 10.1590/s0066-782x1998001000008. Arq Bras Cardiol. 1998. PMID: 10347937 Clinical Trial. Portuguese.
PURPOSE: Multicenter, open and non-controlled study to evaluated the efficacy and the tolerability of a low-dose combination of two anti-hypertensive agents: a cardioselective beta-blocker, bisoprolol (2.5 and 5.0 mg) with 6.25 mg of hydrochlorothiazide. METHODS: On …
PURPOSE: Multicenter, open and non-controlled study to evaluated the efficacy and the tolerability of a low-dose combination of two anti-hyp …
Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine.
Breithaupt-Grögler K, Ungethüm W, Meurer-Witt B, Belz GG. Breithaupt-Grögler K, et al. Eur J Clin Pharmacol. 2001 Jul;57(4):275-84. doi: 10.1007/s002280100323. Eur J Clin Pharmacol. 2001. PMID: 11549204 Clinical Trial.
METHODS: In three separate, double-blind, placebo-controlled, four-way cross-over studies in healthy volunteers (n = 16 each), single oral doses of imidapril 10 mg (I), hydrochlorothiazide 12.5 mg (H), bisoprolol 5 mg (B) and nilvadipine 8 mg (N) were administered a …
METHODS: In three separate, double-blind, placebo-controlled, four-way cross-over studies in healthy volunteers (n = 16 each), single oral d …
Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension.
Benetos A, Consoli S, Safavian A, Dubanchet A, Safar M. Benetos A, et al. Am Heart J. 2000 Oct;140(4):E11. doi: 10.1067/mhj.2000.108834. Am Heart J. 2000. PMID: 11011336 Clinical Trial.
A randomized, multicenter, double-blind, parallel group study was conducted to compare the efficacy and safety of bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg (n = 84) to amlodipine 5 mg (n = 80) in isolated systolic hypertension in patients older than 60 years. .. …
A randomized, multicenter, double-blind, parallel group study was conducted to compare the efficacy and safety of bisoprolol 2.5 mg/ …
Efficacy of newer versus older antihypertensive drugs in black patients living in sub-Saharan Africa.
M'Buyamba-Kabangu JR, Anisiuba BC, Ndiaye MB, Lemogoum D, Jacobs L, Ijoma CK, Thijs L, Boombhi HJ, Kaptue J, Kolo PM, Mipinda JB, Osakwe CE, Odili A, Ezeala-Adikaibe B, Kingue S, Omotoso BA, Ba SA, Ulasi II, Staessen JA; Newer versus Older Antihypertensive Agents in African Hypertensive Patients Trial (NOAAH) Investigators. M'Buyamba-Kabangu JR, et al. J Hum Hypertens. 2013 Dec;27(12):729-35. doi: 10.1038/jhh.2013.56. Epub 2013 Jun 27. J Hum Hypertens. 2013. PMID: 23803591 Free PMC article. Clinical Trial.
After 4 weeks off treatment, 183 of 294 screened patients were assigned to once daily bisoprolol/hydrochlorothiazide 5/6.25 mg (n=89; R) or amlodipine/valsartan 5/160 mg (n=94; E) and followed up for 6 months. To control blood pressure (<140/<90 mm Hg), bis
After 4 weeks off treatment, 183 of 294 screened patients were assigned to once daily bisoprolol/hydrochlorothiazide 5/6.25 mg …
Bioequivalence study of 2 formulations of film-coated tablets containing a fixed dose combination of bisoprolol fumarate 5 mg and hydrochlorothiazide 6.25 mg in healthy subjects.
Tjandrawinata RR, Setiawati E, Yunaidi DA, Santoso ID, Setiawati A, Susanto LW. Tjandrawinata RR, et al. Drug Res (Stuttg). 2013 May;63(5):243-9. doi: 10.1055/s-0033-1334922. Epub 2013 Mar 28. Drug Res (Stuttg). 2013. PMID: 23539427 Clinical Trial.
BACKGROUND: The present study was conducted to compare the bioavailability of 2 formulations of fixed-dose combination of bisoprolol fumarate 5 mg and hydrochlorotiazide (HCT) 6.25 mg film-coated tablet (test and reference formulations). ...The differences between the test …
BACKGROUND: The present study was conducted to compare the bioavailability of 2 formulations of fixed-dose combination of bisoprolol
41 results